State-of-the-art approaches for heterologous expression of bispecific antibodies targeting solid tumors

Abstract

Bispecific antibodies (bsAbs) belong to the group of promising biotherapeutics, as their structural and functional features provide versatility. To put it simply, bsAbs bind two antigens or two epitopes on one antigen simultaneously, moreover, they are capable of directing effector immune cells to cancer cells and delivering payloads (radionuclides, toxic agents, and immunological payloads) to target cells, thus offering a broad spectrum of clinical applications. Current review is focused on bsAbs platform engineering technologies, current progress and prospects in utilization and selection of various heterologous expression systems for protein production. Furthermore we share our view on the future of the bsAbs development for solid tumor therapy.